Professional Documents
Culture Documents
Prepared For:
Michael Spada
Director of Product Marketing - IEEE
445 Hoes Lane
Piscataway, NJ 08855-1331, USA
Prepared By:
Patents have a highly skewed value and impact distribution. Very few patents
have a major technological impact or have significant financial value. Many more
patents have limited technological or financial value.
The aim of this report is to isolate these important and valuable patents, and
identify which of them build upon IEEE science. We first identified patents that
are cited frequently by later patents, since such patents have a strong impact on
technological developments. From among these high impact patents, we then
identified those that cite at least four different IEEE articles as prior art.
A list of almost 800 high impact patents that build extensively upon IEEE science
is provided in Appendix A. From among this list, in this report we highlight 48
patents, six each from eight different industries (Computer Hardware; Computer
Software; Semiconductors; Information Storage; Optics; Telecommunications;
Robotics; and Medical Devices).
ii
A patent from an Israeli semiconductor firm named Saifun for a non-volatile
EEPROM (electrically erasable and programmable) memory cell. The patent was
invented by the firm’s CEO Boaz Eitan. Eitan who is a former employee of Intel,
is considered to be one of the world’s leading experts on non-volatile memory
components. Saifun signed Licensing deals with Sony, Fujitsu, Infineon and
others that are expected to generate royalties in the hundreds of millions of
dollars. In 2007 Spansion purchased Saifun to gain access to its non-volatile
memory for $368 million. Boaz remains CEO of Saifun, which runs as a wholly
owned subsidiary of Spansion.
A medical device patent from Georgia Tech with the title “Microneedle devices
and methods of manufacture and use thereof.” Microneedle technology is a new,
microscopic injectable drug delivery method that can target specific layers of the
skin. The novel dual-delivery method combines the advantages of hypodermic
syringes and transdermal patches. There are many medicines that cannot be used
with transdermal patches because they will not penetrate the skin. The
microneedle patches solve the problem painlessly, because unlike hypodermic
needles the microneedles are too small to stimulate nerve endings. Moreover, the
microneedle patches allow better dosage control and are seen to be particularly
useful for insulin because the dosage could be more easily adjusted and the
injections can be pain free. Finally, the technology holds promise for mass
vaccinations because they’re cost effective and could be applied by people with
minimal training. In 2007 Apogee Technology signed an exclusive license with
Georgia Tech to use the microneedle technology in its PyraDerm drug delivery
system. The microneedle patent lists several IEEE articles as prior art.
iii
referenced in this patent suggest that IEEE science provided an important
foundation for this technological development.
iv